HSJN(SZ:002817)2022-11-11 06:02Group 1: Financial Performance and Investment - The company has seen a 43.76% increase in R&D investment in 2021 compared to the previous year, reflecting its ongoing commitment to research and development [1][2] - The company has not engaged in direct financing since its IPO, relying instead on loans for specific projects, such as the "Hollow Capsule Intelligent Manufacturing New Model" project [1] - The company maintains a low level of interest-bearing debt, benefiting from favorable bank loan rates [1] Group 2: Production Capacity and Market Position - Anhui Huangshan Capsule Co., Ltd. is one of the largest manufacturers of pharmaceutical hollow capsules, with an annual production capacity exceeding 40 billion capsules [2] - The company utilizes advanced intelligent manufacturing technology, allowing for the production of various specifications and customized services [2] Group 3: Shareholder Concerns and Market Performance - The company's stock price has declined significantly from a peak of 83 yuan to below 8 yuan, raising concerns among shareholders about the company's future [2] - The company is focused on steady operations and aims to create sustainable long-term returns for investors despite market fluctuations [2]